Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2024 Feb 28

PMID 38414525

Authors

Xianzhe Yu

Lingling Zhu

Affiliations

Soon will be listed here.

Abstract

Although the frequency of bone metastases from breast cancer has increased, effective treatment is lacking, prompting the development of nanomedicine, which involves the use of nanotechnology for disease diagnosis and treatment. Nanocarrier drug delivery systems offer several advantages over traditional drug delivery methods, such as higher reliability and biological activity, improved penetration and retention, and precise targeting and delivery. Various nanoparticles that can selectively target tumor cells without causing harm to healthy cells or organs have been synthesized. Recent advances in nanotechnology have enabled the diagnosis and prevention of metastatic diseases as well as the ability to deliver complex molecular "cargo" particles to metastatic regions. Nanoparticles can modulate systemic biodistribution and enable the targeted accumulation of therapeutic agents. Several delivery strategies are used to treat bone metastases, including untargeted delivery, bone-targeted delivery, and cancer cell-targeted delivery. Combining targeted agents with nanoparticles enhances the selective delivery of payloads to breast cancer bone metastatic lesions, providing multiple delivery advantages for treatment. In this review, we describe recent advances in nanoparticle development for treating breast cancer bone metastases.

Citing Articles

Automatic detecting multiple bone metastases in breast cancer using deep learning based on low-resolution bone scan images.

Shi J, Zhang R, Yang Z, Chen Z, Hao Z, Huo L Sci Rep. 2025; 15(1):7876.

PMID: 40050676 PMC: 11885835. DOI: 10.1038/s41598-025-92594-5.

Plant protein-derived anti-breast cancer peptides: sources, therapeutic approaches, mechanisms, and nanoparticle design.

Zhang D, Yuan Y, Zeng Q, Xiong J, Gan Y, Jiang K Front Pharmacol. 2025; 15:1468977.

PMID: 39898323 PMC: 11783187. DOI: 10.3389/fphar.2024.1468977.

New insights into non-small cell lung cancer bone metastasis: mechanisms and therapies.

Xue M, Ma L, Zhang P, Yang H, Wang Z Int J Biol Sci. 2024; 20(14):5747-5763.

PMID: 39494330 PMC: 11528464. DOI: 10.7150/ijbs.100960.

Neutrophil-targeted liposomal platform: A shift in novel approach for early detection and treatment of cancer metastasis.

Li C, Zhang K, Cheng Z, Wang L, Li Z, Shen C Asian J Pharm Sci. 2024; 19(5):100949.

PMID: 39474126 PMC: 11513460. DOI: 10.1016/j.ajps.2024.100949.

Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer.

Oehler J, Rajapaksha W, Albrecht H J Pers Med. 2024; 14(7).

PMID: 39063977 PMC: 11278299. DOI: 10.3390/jpm14070723.

References

Hou Y, Bu W, Ai H, Lu Z, Lammers T . Stimuli-Responsive Nanotheranostics. Adv Healthc Mater. 2021; 10(5):e2100243. DOI: 10.1002/adhm.202100243. View

Salerno M, Cenni E, Fotia C, Avnet S, Granchi D, Castelli F . Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr Cancer Drug Targets. 2010; 10(7):649-59. DOI: 10.2174/156800910793605767. View

Charlesworth C, Hsu I, Wilkinson A, Nakauchi H . Immunological barriers to haematopoietic stem cell gene therapy. Nat Rev Immunol. 2022; 22(12):719-733. PMC: 8929255. DOI: 10.1038/s41577-022-00698-0. View

Ihle C, Wright-Hobart S, Owens P . Therapeutics targeting the metastatic breast cancer bone microenvironment. Pharmacol Ther. 2022; 239:108280. DOI: 10.1016/j.pharmthera.2022.108280. View

Kan C, Vargas G, Pape F, Clezardin P . Cancer Cell Colonisation in the Bone Microenvironment. Int J Mol Sci. 2016; 17(10). PMC: 5085707. DOI: 10.3390/ijms17101674. View

Fuentes-Chust C, Parolo C, Rosati G, Rivas L, Perez-Toralla K, Simon S . The Microbiome Meets Nanotechnology: Opportunities and Challenges in Developing New Diagnostic Devices. Adv Mater. 2021; 33(18):e2006104. DOI: 10.1002/adma.202006104. View

Nunez C, Estevez S, Del Pilar Chantada M . Inorganic nanoparticles in diagnosis and treatment of breast cancer. J Biol Inorg Chem. 2018; 23(3):331-345. DOI: 10.1007/s00775-018-1542-z. View

Allocca G, Hughes R, Wang N, Brown H, Ottewell P, Brown N . The bone metastasis niche in breast cancer-potential overlap with the haematopoietic stem cell niche . J Bone Oncol. 2019; 17:100244. PMC: 6582079. DOI: 10.1016/j.jbo.2019.100244. View

He Y, Huang Y, Huang Z, Jiang Y, Sun X, Shen Y . Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer. J Control Release. 2017; 264:76-88. DOI: 10.1016/j.jconrel.2017.08.024. View

10.

Blum J, Savin M, Edelman G, Pippen J, Robert N, Geister B . Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2008; 7(11):850-6. DOI: 10.3816/CBC.2007.n.049. View

11.

Akonnor A, Makise M, Kuniyasu A . CXCR4-Targeted Necrosis-Inducing Peptidomimetic for Treating Breast Cancer. ACS Omega. 2023; 8(27):24467-24476. PMC: 10339399. DOI: 10.1021/acsomega.3c02415. View

12.

Lee H, Gaddy D, Ventura M, Bernards N, De Souza R, Kirpotin D . Companion Diagnostic Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines. Theranostics. 2018; 8(9):2300-2312. PMC: 5928891. DOI: 10.7150/thno.21670. View

13.

Yardley D, Hart L, Bosserman L, Salleh M, Waterhouse D, Hagan M . Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen. Breast Cancer Res Treat. 2012; 137(2):457-64. PMC: 3539071. DOI: 10.1007/s10549-012-2341-9. View

14.

Raj S, Khurana S, Choudhari R, Kesari K, Kamal M, Garg N . Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. Semin Cancer Biol. 2019; 69:166-177. DOI: 10.1016/j.semcancer.2019.11.002. View

15.

Chen S, Liu T, Chuang C, Chen H, Chiang W, Chiu H . Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer. J Mater Chem B. 2020; 8(17):3789-3800. DOI: 10.1039/d0tb00046a. View

16.

Zhang Y, Wang Y, Zhu A, Yu N, Xia J, Li J . Dual-Targeting Biomimetic Semiconducting Polymer Nanocomposites for Amplified Theranostics of Bone Metastasis. Angew Chem Int Ed Engl. 2023; 63(2):e202310252. DOI: 10.1002/anie.202310252. View

17.

Sun W, Ge K, Jin Y, Han Y, Zhang H, Zhou G . Bone-Targeted Nanoplatform Combining Zoledronate and Photothermal Therapy To Treat Breast Cancer Bone Metastasis. ACS Nano. 2019; 13(7):7556-7567. DOI: 10.1021/acsnano.9b00097. View

18.

Ross M, Esser A, Fox G, Schmieder A, Yang X, Hu G . Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases. Cancer Res. 2017; 77(22):6299-6312. PMC: 5841166. DOI: 10.1158/0008-5472.CAN-17-1225. View

19.

Stefanick J, Ashley J, Bilgicer B . Enhanced cellular uptake of peptide-targeted nanoparticles through increased peptide hydrophilicity and optimized ethylene glycol peptide-linker length. ACS Nano. 2013; 7(9):8115-27. DOI: 10.1021/nn4033954. View

20.

Wang X, Yu B, Wu Y, Lee R, Lee L . Efficient down-regulation of CDK4 by novel lipid nanoparticle-mediated siRNA delivery. Anticancer Res. 2011; 31(5):1619-26. View